Gilead Sciences, a privately owned company headquartered in the US, was founded in 1987. With approximately 13,690 employees, the company functions as a tier 1 media tech buyer. Gilead Sciences specializes in biotechnology research, focusing on bringing forward medicines for life-threatening diseases. The company's operations involve its employees collaborating through science to address medical challenges.
On July 9, 2026, Gilead Sciences received FDA approval for its breast cancer drug, Trodelvy (sacituzumab govitecan-hziy), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Previously, on July 7, 2026, Gilead Sciences Inc. patented new protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors, potentially useful for cancer treatment. An exemplified compound demonstrated 48% bioavailability in beagle dog plasma at 30 mg/kg p.o.
Similar Companies
Subscribe for full access to Gilead Sciences's profile
Gilead Sciences offers 2 products in the media and telecoms services industry. Gilead Sciences's product portfolio comprises of search, social, and retail media.
Subscribe for full access to Gilead Sciences's products in full detail
Subscribe for full access to Gilead Sciences's revenue in full detail
Subscribe for full access to Gilead Sciences's products in full detail 
